drugset / Trial / NCT02435680

Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)

NCT02435680

Phase 2 Completed 50 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

To determine whether MCS110 antibody therapy improves the efficacy of carboplatin and gemcitabine (carbo/gem) in advanced TNBC patients

Timeline

Start
2015-08-10
Primary completion
2020-01-04
Completion
2020-03-23

Drugs

EvaluationDrugModalityDoseRoute
Subject MCS110 Monoclonal antibody Intravenous
Background Carboplatin Small molecule Intravenous
Background Gemcitabine Small molecule Intravenous